AI Assisted Mechanistic and Translational Evaluation of Moringa oleifera in Alzheimer’s disease: A Preclinical-to-Clinical Study

Abstract

Alzheimer’s disease (AD) is a multifactorial neurodegenerative disorder characterized by amyloid-β deposition, tau pathology, oxidative stress, and chronic neuroinflammation. Current therapeutic options provide only symptomatic relief, underscoring the need for novel, multi-target strategies. This study investigates the potential of Moringa oleifera as a phytotherapeutic candidate for AD by systematically reviewing preclinical and translational evidence. The plant is rich in bioactive compounds, particularly flavonoids such as quercetin and kaempferol, which demonstrate antioxidant, anti-inflammatory, and cholinesterase inhibitory properties. Computational analyses, including molecular docking and pharmacokinetic predictions, suggest favorable drug-like characteristics and interactions with key AD-related pathways, including NF-κB, Nrf2, and amyloidogenic mechanisms. Experimental studies in vitro and in vivo consistently report neuroprotective effects, including reduced oxidative stress, decreased amyloid burden, improved cognitive performance, and modulation of inflammatory mediators. Despite these promising findings, clinical validation remains limited, with challenges related to standardized formulations and the absence of large-scale human trials. Overall, Moringa oleifera emerges as a promising adjunct candidate for AD management, warranting further translational and clinical investigations to establish its therapeutic efficacy and safety in humans.